Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response

Table 1 Surface molecules expression of 4 kinds of DCs stimulated with lysates (n = 10, mean ± SD, %)

Surface molecules	DC	Wtp53DC	LyDC	Lywtp53
B7-1	36.70 ± 0.07	61.77 ± 0.08	67.20 ± 0.05	86.70 ± 0.07a
B7-2	5.27 ± 0.01	9.90 ± 0.04	9.13 ± 0.03	18.77 ± 0.08a
MHC-I	44.03 ± 0.04	69.13 ± 0.05	68.10 ± 0.03	87.20 ± 0.05a
MHC-II	17.13 ± 0.12	31.10 ± 0.31	32.73 ± 0.23	56.70 ± 0.07a

^aP < 0.05 vs any group of DC, wtp53DC and LyDC.

Table 2 Immune protection of DCs (mean ± SD, n = 10)

Group	Tumor diameter after inoculation (mm)
	d 10	d 13	d 16	d 19
Control	3.72 ± 0.01	6.70 ± 0.02	7.10 ± 0.09	9.90 ± 0.02
DC	3.70 ± 0.01	5.70 ± 0.08	6.10 ± 0.04	9.70 ± 0.08
Wtp53DC	3.07 ± 0.01	6.90 ± 0.04	7.13 ± 0.03	8.22 ± 0.08
LyDC	4.03 ± 0.04	6.13 ± 0.05	7.10 ± 0.03	8.77 ± 0.05
Lywtp53	3.13 ± 0.02	3.10 ± 0.31a	2.73 ± 0.23a	3.70 ± 0.07a

^aP < 0.05 vs control, DC, wtp53DC and LyDC group.

Table 3 Immune treatment of DCs (mean ± SD, n = 10)

Group	Tumor diameter after inoculation (mm)
	d 7	d 12	d 15	d 18
Control	5.72 ± 0.02	7.88 ± 0.09	9.20 ± 0.11	11.90 ± 0.09
DC	4.70 ± 0.03	7.71 ± 0.08	9.02 ± 0.04	10.70 ± 0.68
Wtp53DC	5.03 ± 0.09	6.90 ± 0.09	7.13 ± 0.11	8.29 ± 0.05
LyDC	5.06 ± 0.01	6.13 ± 0.08	7.10 ± 0.05	8.77 ± 0.03
Lywtp53	5.19 ± 0.09	5.10 ± 0.39	6.73 ± 0.66a	6.79 ± 0.77a

^aP < 0.05 vs control, DC, wtp53DC and LyDC group.